Business
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
LTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to
About this update from Verrica Pharmaceuticals Inc.
[{"type":"text","content":"LTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options WEST CHESTER, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the first patient has been dosed in the Company’s Phase 2 trial of LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. “We are pleased to announce the initial dosing of the first patient in our Phase 2 study of LTX-315 for the treatment of basal cell carcinoma, Verrica’s first planned study of LTX-315,” said Dr. Gary Goldenberg, Verrica’s Chief Medical Officer. “Non-melanoma skin cancers, including basal cell and squamous cell carcinomas, are the most common form of cancer in the U.S., with over 5 million diagnoses each year, and there is a high unmet need for new treatments. While basal cell carcinoma is our lead indication for LTX-315, we also look forward to potentially expanding the program into squamous cell carcinoma in the future.” “Current invasive treatments for basal cell carcinoma can cause bleeding, pain, infection and scarring,” said Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego and lead primary investigator in the trial. “LTX-315 has the potential to bring patients a much-needed non-surgical treatment option. I am thrilled to lead the investigation of LTX-315 in this Phase 2 trial.” About the Phase 2 Trial of LTX-315 The Phase 2 trial is a 3-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy of LTX-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study is expected to enroll approximately 66 adult subjects with a histological diagnosis of basal cell carcinoma in at least one eligible target lesion. For additional information about this clinical trial, please visit www.clinicaltrials.gov, identifier NCT05188729. About LTX-315 LTX-315 is a potent...